Study links sustained Zepbound use to lower healthcare costs
A real-world study of more than 15,000 adults over age 55 found that sustained Zepbound use was associated with sharply lower healthcare spending over time versus untreated patients. After six months, monthly costs were up to 15% lower and after 12 months 38% lower, supporting Lilly’s case for broader coverage with Medicare, employers, and other payers.